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M
idgestational placental haemorrhage threatens both
mother and fetus. Reconciling maternal haemostasis
with fetal well-being is a major therapeutic challenge.
Between 24 and 26 weeks gestation in particular, despite aggres-
sive obstetric and neonatal management, fetal survival is uncer-
tain and survivor morbidity considerable (1).
Case report
A 42-year-old gravida 6 para 5 was referred at 24 +5 weeks ges-
tation for persistent vaginal haemorrhage since week 9. Admis-
sion haemoglobin (Hb) was 7.7 g/dl. Cardiovascular status was
stable despite ongoing heavy bleeding; transfusion of two units
of packed red blood cells increased the Hb to only 8.1 g/dl. Per-
sonal and family haemorrhagic and thromboembolic history was
negative; no antiplatelet drugs had been taken (platelet count:
291 G/l).There were no risk factors for, nor a previous history of,
placental abruption. Fibrinogen levels and prothrombin and acti-
vated partial thromboplastin times were normal, as were the lev-
els of von Willebrand factor (ristocetin cofactor activity) and
factor XIII (amidolytic activity). D-dimers were elevated at
1,800 ng/ml; hyperfibrinolysis was excluded (ROTEM™ analy-
sis). Ultrasonography revealed a 71×51×85 mm retroplacental
haematoma and a normal-for-dates fetus.
Given the active bleeding, immediate danger to maternofetal
well-being, absence of therapeutic alternatives, and virtual cer-
tainty of adverse fetal outcome from delivery at this gestational
age, we evaluated the off-label use of human recombinant factor
VIIa (rFVIIa). A literature search revealed no reports of rFVIIa
use in pregnancy. We estimated the thrombotic risk attributable
to rFVIIa treatment to be <3% for the mother and less for the
fetus (a literature search and manufacturer’s data [NovoNordisk,
Bagsværd, Denmark] provided no evidence that rFVIIa crossed
the placenta), with a reasonable probability of successful hae-
mostatic response. After we informed the patient of the nature of
the drug, the potential complications (including thromboembol-
ism and death), and the absence of reported experience in this in-
dication, she signed an informed consent form. Based on an un-
published report obtained from the manufacturer of rFVIIa use
(NovoSeven
®
, 30 µg/kg bodyweight [BW]) in a pregnant woman
with congenital factor VII deficiency, and to minimise maternal
thrombotic risk, we opted for a dose of 20 µg/kg BW (2.4 mg) in-
travenously (iv). Contractions were managed with hexoprenaline
iv (Gynipral
®
, Nycomed, Waedenswil, Switzerland) and fetal
lung maturation was induced with steroids (betamethasone
[Celestone
®
] 2×12 mg iv; Essex, Lucerne, Switzerland).
Active bleeding virtually ceased within hours after rFVIIa
administration although old blood and blood clots continued to
discharge over the following weeks at levels not requiring trans-
fusion.The intrauterine haematoma shrank by two thirds (Fig. 1).
Maternal Hb increased to 10.9 g/dl after treatment with iv iron
(1,200 mg in total; Venofer
®
, Vifor International, St Gallen,
Switzerland) and recombinant human erythropoietin (total
20,000 U; Eprex
®
, Janssen-Cilag, Baar, Switzerland). At 31+3
weeks gestation, premature rupture of membranes prompted
antibiotic prophylaxis iv. Caesarean section the next day deliver-
ed a clinically healthy girl (1,720 g, 53rd percentile, normal um-
bilical artery pH, normal Apgar) who was admitted to neonatal
intensive care for prematurity but did not require mechanical
ventilation. Maternal postpartum recovery was uneventful, and
the patient was discharged on day 5. We observed no side effects
from rFVIIa treatment in either mother or fetus. Placental pa-
thology confirmed the ultrasound diagnosis of partial placental
abruption and revealed an old extensive retroplacental haemato-
ma, but no signs of chorioamnionitis.
Discussion
According to a cell-based model of coagulation, factor VII plays
a key role in initiating haemostasis. Administration of rFVIIa
maintains haemostasis by enhancing thrombin generation, lead-
ing to the formation of a stable fibrin clot (2). Literature on the
obstetric applications of rFVIIa is sparse and mainly limited to
case reports and case series on the treatment of postpartum
haemorrhage (3). We were aware of the difficulty of gauging
thromboembolic risk in off-label patients in general and in our
patient in particular. Reports of rFVIIa-related thromboembolic
events have increased dramatically in recent years. O’Connell et
al. reviewed 431 reports but due to data analysis deficiencies
failed to provide their incidence or frequency (4). In on-label
treated patients, the reported thromboembolic complication
(TEC) rate is <1% versus ≥10% in off-label patients (5). Recent
meta-analyses of off-label rFVIIa applications in high-risk sur-
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gical patients report TEC rates of 7.7% (n = 1,067) and 7.1%
(n = 507) (6, 7); however, these figures need to be set against the
basal TEC risk of 5.1% and 5.2%, respectively, in controls with-
out rFVIIa treatment. We estimated the basal TEC risk as being
clearly lower than either of these figures (between 0.1 and 0.01%
per year) in our 42-year-old patient with no concomitant morbid-
ity or medication, and a negative personal and family throm-
boembolic history.
Pregnancy is a prothrombotic risk state that compounds
relative TEC risk five-fold (8). The overall venous thromboem-
bolic risk associated with pregnancy, 1/1,000 to 1/2,000 de-
liveries (9), further supports our estimates, as does the absence of
thromboembolism in the series of 79 women treated with rFVIIa
for postpartum haemorrhage (3). In view of all the above, we es-
timated that the mother’s thrombotic risk attributable to rFVIIa
treatment was <3%.To minimise this risk we opted for a low dose
of rFVIIa, following Franchini et al. who reported (mostly
single) doses of 16.7–48 µg/kg body weight (3). We estimated
the risk to the fetus as lower still given the low probability of sig-
nificant drug transfer across the placenta, based on a negative lit-
Figure 1: Sonogram of retroplacental
haematoma on admission (24 +5 weeks
of gestation; 71×51 mm) and at 28 +5
weeks (59×14 mm).
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